An interventional study of AI Chatbot for Breast Cancer Patient Education and Empowerment in Breast Cancer Early Stage Breast Cancer (Stage 1-3), sponsored by Mostafa Shaban. Not yet recruiting at 1 site in Egypt. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.
Sponsored by Mostafa Shaban · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 248 studies in Breast Neoplasms with a site in Egypt — 58 open to participants now, 68 under way, 5 of them phase 3. Breast Neoplasms · Egypt.
Among the 248 studies in Breast Neoplasms with a site in Egypt, this one is the 42nd largest by planned enrollment of the 183 interventional ones that give a count, is one of 25 that started in 2025, is one of 85 with no phase, reaches primary completion later than 20 of the 67 other live ones, and was the 200th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →58 of the 248 studies in Breast Neoplasms with a site in Egypt are open now. Recruiting first, the newest first:
Cairo University · Sites in Egypt
Ages 65–75 · Women only
National Cancer Institute, Egypt · Sites in Egypt
Ages 18–65 · Women only
Adly A Adam · Sites in Egypt
Ages 40–50 · Women only
Sohag University · Sites in Egypt
Ages 18–80
Alexandria University · Sites in Egypt
Ages 18–70 · Women only
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
248 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 46 · Phase 3 47 · Phase 4 11
First in 1997; this study’s year is marked. 25 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 122 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 70 across the 183 interventional studies, 100 across the 63 observational. Of the 131 that completed or were terminated, 20 (15%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 248 have an industry lead sponsor. The 10 most frequent:
Mostafa Shaban is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Mostafa Shaban has 1 study filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
17 of the studies in Breast Neoplasms with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06596122Abdelrahman MahmoudVitamin D Supplementation in Breast Cancer Patients | 2026-11-30 |
| NCT07095569National Cancer Institute, EgyptShoulder Denervation for Post Mastectomy Irradiation Shoulder Pain | 2026-12-01 |
| NCT07650305National Cancer Institute, EgyptBilevel Erector Spinae Plane Block Versus Pectoserratus Block for Analgesia in Modified Radical Mastectomy | 2026-12-01 |
| NCT07894133Adly A AdamGait Parameters in Breast Cancer Receiving Chemotherapy Patients | 2026-12-01 |
| NCT01101425European Organisation for Research and Treatment of Cancer - EORTCMale Breast Cancer: Understanding the Biology for Improved Patient Care | 2026-12-31 |
Add all 17 to your calendar (.ics) → With an account.
Among the 248 studies in Breast Neoplasms with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to investigate the impact of an AI-powered chatbot intervention on improving knowledge, attitudes, and empowerment in breast cancer patients. The study focuses on female breast cancer patients, aged 18 years or older, who are receiving treatment at Kafr El-Sheikh University Hospital in Egypt.
The main questions it aims to answer are:
Can the AI chatbot intervention improve breast cancer knowledge compared to standard care?
Can the AI chatbot intervention positively influence attitudes toward AI in healthcare?
Does the AI chatbot intervention enhance patient empowerment in managing breast cancer?
Researchers will compare:
Intervention group (AI chatbot + standard care) to control group (standard care alone) to see if the AI chatbot intervention leads to greater improvements in knowledge, more positive attitudes towards AI, and higher perceived empowerment.
Participants will:
Engage with an AI-powered chatbot designed to provide personalized education on breast cancer, treatment options, and emotional support.
Complete pre- and post-intervention assessments to measure changes in knowledge, attitudes toward AI, and empowerment.
Receive standard care, including routine oncology consultations and nursing support, alongside the chatbot intervention (for the intervention group).
This study explores the integration of AI-powered chatbots in breast cancer care to enhance patient education, self-management, and psychosocial support. Breast cancer is often accompanied by a range of psychological challenges, including anxiety and uncertainty about treatment options, side effects, and overall prognosis. Traditional healthcare systems struggle to provide continuous support, which is where AI technology can offer a solution by enabling 24/7 access to information and emotional support.
The study design employs a quasi-experimental approach, where 122 breast cancer patients were recruited from Kafr El-Sheikh University Hospital. Participants were randomly assigned to one of two groups:
Intervention Group (n=61): Participants in this group received standard care, which includes routine consultations with oncology specialists and nurses, in addition to an AI chatbot intervention. The chatbot delivered personalized educational content about breast cancer, treatment options, and self-care. It also offered emotional support by answering queries and providing motivational messages.
Control Group (n=61): Participants in this group received only standard care, which consisted of regular oncology consultations and nursing support without the chatbot.
The AI chatbot intervention is designed to:
Improve knowledge about breast cancer, treatment side effects, symptom management, and emotional well-being.
Foster positive attitudes toward AI in healthcare by providing a reliable, non-judgmental source of information.
Enhance empowerment by allowing patients to actively engage with their care information outside of regular hospital visits.
Participants' knowledge, attitudes toward AI, and empowerment were assessed at two time points:
Baseline (before the intervention)
Post-intervention (after 4 weeks of engaging with the chatbot)
The primary outcome of the study is to evaluate improvements in breast cancer-related knowledge, measured through a questionnaire that assesses knowledge in key areas such as early detection, treatment options, side effects, and AI's role in healthcare. The secondary outcomes focus on attitudes toward AI and perceived empowerment, assessed through validated Likert scales designed for this purpose.
This study will provide valuable insights into the feasibility and efficacy of AI-powered chatbots in enhancing patient care for breast cancer patients, especially in resource-limited settings. Furthermore, it aims to contribute to the growing body of evidence supporting the use of digital health technologies in oncology nursing and patient empowerment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Female participants diagnosed with breast cancer, regardless of cancer stage.
Age 18 years or older.
Ability to read and communicate in Arabic to interact with the AI chatbot.
Willingness to participate in the study and to engage with the AI chatbot for the duration of the intervention.
Ability to provide .
Exclusion Criteria:
Participants with cognitive impairments or serious mental health conditions that may hinder understanding or participation in the study.
Patients currently receiving palliative care, as they may prioritize symptom management over educational interventions.
Participants who are physically unable to engage with the study's digital tools or complete assessments (e.g., due to severe illness).
Individuals who are unable to communicate in Arabic, as the AI chatbot intervention is designed in Arabic.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this arm will receive standard oncology care in addition to interacting with an AI-powered chatbot. The chatbot will provide personalized educational content on breast cancer, treatment options, side effects, and offer emotional support. Participants will engage with the chatbot for 4 weeks, with assessments at baseline and post-interventi
Behavioral: AI Chatbot for Breast Cancer Patient Education and Empowerment
Participants in this arm will receive standard oncology care only, including routine consultations with oncology specialists and nurses. They will not have access to the AI chatbot intervention.
The AI Chatbot for Breast Cancer Patient Education and Empowerment is a digital health intervention that leverages artificial intelligence to provide personalized educational content and emotional support to breast cancer patients. The chatbot delivers information on breast cancer management, treatment options, side effects, and self-care practices. It is available 24/7, offering real-time answers to patient queries and tailored suggestions based on their treatment path. The aim is to increase patient knowledge, improve attitudes toward AI, and empower patients to take a more active role in their care. The chatbot intervention is provided alongside standard oncology care at Kafr El-Sheikh University Hospital.
Breast Cancer Knowledge Improvement
This outcome measures the change in breast cancer knowledge from baseline to post-intervention for participants who used the AI chatbot compared to the control group. Knowledge is assessed using the Artificial Intelligence of Breast Cancer Questionnaire, which covers topics such as treatment options, side effects, symptom management, and AI's role in healthcare.
Time frame: 2 months
Plan to share: Undecided — We currently do not plan to share individual participant data (IPD) outside of the research team due to concerns about participant confidentiality and the sensitive nature of the data collected. The study includes personal health information that is protected under ethical guidelines and privacy regulations. Additionally, sharing IPD may present challenges related to data security and informed consent, as participants have not explicitly consented to broader data sharing. However, the study's aggregate findings will be made publicly available through peer-reviewed publications and presentations
Start is estimated for Apr 2025; primary completion for Jul 2025, 2 months later.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 2 months is below that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mostafa Shaban